• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB

MESOBLAST LIMITED - News & Media

0.43% ! $2.32
Market Cap $2.969B  !
Healthcare Biotechnology
Add to My Watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Articles & Videos

Mesoblast falls -10% on earnings report; -US$100M loss

Mesoblast had HotCopper users divided on whether the company's fortunes are anything to worry about based on the nature of a Friday webcast.

29 Aug 2025 11:52 (AEST)

The market shrugged at Mesoblast's latest FDA win. Is it just another Droneshield?

Mesoblast (ASX:MSB) has revealed the US FDA has given its flagship drug a 7 year exclusivity period, blocking...

15 May 2025 11:20 (AEST)

Mesoblast dips on 'belief' it's not subject to US tariffs – despite Singaporean lab

Mesoblast (ASX:MSB) has seen shares fall just shy of -3% heading into lunchtime trades despite apparent tariff relief.

04 Apr 2025 12:31 (AEDT)

Mesoblast kicks off treatment for first 3 kids with graft-host disease. So why are shares down?

otCopper favourite Mesoblast (ASX:MSB) has announced it's begun treating the first 3 children with skin graft-versus-host disease in the US, at the same time the company received medicare (US) and medicaid coverage.

31 Mar 2025 12:55 (AEDT)

Mesoblast kicks off Ryoncil sales in US but shareholders eager for revenue

Mesoblast (ASX:MSB) has announced its product Ryoncil is officially available for sale in the US through private health insurance.

27 Mar 2025 11:57 (AEDT)

HotCopper users flock to make sense of darling Mesoblast's 'proposed financing'

If you’ve been paying attention, you know Mesoblast (ASX:MSB) is currently something of an Australian market darling.Just take a look at its recent run. One-year returns are currently up +868%, borne largely from the US FDA’s decision to approve Mesoblast&CloseCurl...

10 Jan 2025 12:44 (AEDT)

Gold Medal Awards: All the biggest ASX winners (and top stock gainers) in 2024

The ASX is barrelling towards closing out 2024 with another red day on New Year’s Eve, but that doesn’t mean the year as a whole was a bloodbath @ in fact, for much of the Aussie index it’s been quite the year to remember.Even more so, some Australi...

31 Dec 2024 11:40 (AEDT)

Cashed up & ready to go: Mesoblast forges funding deal with top shareholder

Mesoblast (ASX:MSB) is trading up more than 1.75% after striking a funding deal with its largest shareholder Gregory George for AUD$72.7 million in convertible notes.

30 Sep 2024 11:20 (AEST)

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Mesoblast shares fell -4.45% in the first hour of trades on Tuesday as the company announced it has to resubmit an application to the FDA.

09 Jul 2024 10:43 (AEST)

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

14 Mar 2024 13:59 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$2.32 		Change
0.010(0.43%) 		Mkt cap ! $2.969B
Open High Low Value Volume
$2.36 $2.38 $2.25 $15.61M 6.767M

Buyers (Bids)

No. Vol. Price($)
1 50000 $2.31
 

Sellers (Offers)

Price($) Vol. No.
$2.32 35000 2
View Market Depth
Last trade - 16.10pm 11/09/2025 (20 minute delay) ?
Last
$2.32 		  Change
0.010 ( 0.19 %)
Open High Low Volume
$2.37 $2.38 $2.25 1623541
Last updated 15.59pm 11/09/2025 ?
MSB (ASX) Chart

Top Stories

Listen: HotCopper Wire Podcast 024 – Two '4D' stocks to watch, but only one winner

In this HotCopper Wire Week 37 episode, we take a look at the Coles and Woolies legal fight and compare 4DMedical and 4DS Memory.
EVR opens strong with funding, acquisition, and sales agreement announcements EVR has caught attention on the HotCopper forums and across the wider Australian markets today with a flurry of announcements.
Market Close: Aussie traders divorce from US as retreat continues. At least there's 4DX Good Afternoon and welcome to HotCopper’s Market Close for Thursday 11th of September, I’m Jon Davidson. We’ve truly diverted from Wall Street at the start of September with the local bourse retreating once again this week, showing an Australian inv...
Afterpay owner Block shares dip after competitor Klarna lists 30% higher out the gate Afterpay owner Block has seen its shares head towards a -3% drop as the market digests news of Klarna's successful U.S. IPO overnight.
EV Resources snaps up Nevada antimony project; will raise $5.5M for it, Los Lirios EV Resources has come out of its halt with a bang, unveiling the acquisition of the Dollar Antimony Project in Nye County alongside a raise.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.